Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers.

Related collections

Author and article information

Journal

Title: Inflammatory Bowel Diseases

Publisher: Oxford University Press (OUP)

ISSN (Print): 1078-0998

ISSN (Electronic): 1536-4844

Publication date Created: June 2018

Publication date Created: May 18 2018

Publication date Created: April 13 2018

Publication date Other: June 2018

Publication date (Print): May 18 2018

Publication date (Electronic): April 13 2018

Volume: 24

Issue: 6

Pages: 1185-1192

Affiliations

[1 ]VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, USA

[2 ]Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI, USA

[3 ]Department of Statistics, University of Michigan, Ann Arbor, MI, USA

Article

DOI: 10.1093/ibd/izy031

SO-VID: 944863fa-58fa-4a7b-a664-d39e02d158d6

History

Data availability:

Comments

Comment on this article

scite_

Cited by 14

See all cited by

- Version 1